PDF(Pubmed)
Abstract：
UNASSIGNED: Annual influenza vaccinations are recommended for asthma patients to prevent seasonal influenza and influenza-triggered asthma exacerbations. However, data on the beneficial effect of this vaccine on the frequency of asthma exacerbations are conflicting. Therefore, this study aimed to assess the effectiveness of the influenza vaccine in terms of reducing the frequency of asthma-related exacerbations and upper respiratory tract infections among adult patients with asthma.
UNASSIGNED: This retrospective cohort study was performed from January to December 2018 in Muscat Governorate, Oman. A total of 466 patients attending 9 randomly selected primary health centres in Muscat Governorate were enrolled in the study and followed up for one year post vaccination.
UNASSIGNED: Most of the patients were female (70.6%) and had moderate persistent asthma (42.9%). There were 203 patients (43.6%) in the vaccinated group and 263 patients (56.4%) in the non-vaccinated group. A proportion of patients in each group had allergic rhinitis (28.6% and 25.5%, respectively). The frequency of upper respiratory tract infections over the one-year follow-up period was significantly lower in the vaccinated group than in the non-vaccinated group (37.9% versus 73%; relative risk [RR]: 2.299; 95% confidence interval [CI]: 1.834-2.882; P <0.001); however, there was no significant difference in terms of the frequency of asthma exacerbations (41.9% versus 45.2%; RR: 0.925; 95% CI: 0.750-1.141; P >0.050).
UNASSIGNED: The influenza vaccine significantly reduces the frequency of upper respiratory tract infections over the following year. However, it does not significantly reduce the frequency of asthma exacerbations among Omani adults with asthma. Further studies are recommended to support the protective effect of the vaccine in this regard.
UNASSIGNED: This retrospective cohort study was performed from January to December 2018 in Muscat Governorate, Oman. A total of 466 patients attending 9 randomly selected primary health centres in Muscat Governorate were enrolled in the study and followed up for one year post vaccination.
UNASSIGNED: Most of the patients were female (70.6%) and had moderate persistent asthma (42.9%). There were 203 patients (43.6%) in the vaccinated group and 263 patients (56.4%) in the non-vaccinated group. A proportion of patients in each group had allergic rhinitis (28.6% and 25.5%, respectively). The frequency of upper respiratory tract infections over the one-year follow-up period was significantly lower in the vaccinated group than in the non-vaccinated group (37.9% versus 73%; relative risk [RR]: 2.299; 95% confidence interval [CI]: 1.834-2.882; P <0.001); however, there was no significant difference in terms of the frequency of asthma exacerbations (41.9% versus 45.2%; RR: 0.925; 95% CI: 0.750-1.141; P >0.050).
UNASSIGNED: The influenza vaccine significantly reduces the frequency of upper respiratory tract infections over the following year. However, it does not significantly reduce the frequency of asthma exacerbations among Omani adults with asthma. Further studies are recommended to support the protective effect of the vaccine in this regard.
摘要：
■建议哮喘患者每年接种流感疫苗，以预防季节性流感和流感引发的哮喘恶化。然而,关于这种疫苗对哮喘发作频率的有益作用的数据是相互矛盾的.因此,本研究旨在评估流感疫苗在降低成年哮喘患者哮喘相关急性发作和上呼吸道感染频率方面的有效性.
■这项回顾性队列研究于2018年1月至12月在马斯喀特省进行，阿曼。马斯喀特省9个随机选择的初级保健中心共有466名患者被纳入研究，并在接种疫苗后随访一年。
■大多数患者为女性（70.6%），患有中度持续性哮喘（42.9%）。接种疫苗组中有203名患者（43.6％），未接种疫苗组中有263名患者（56.4％）。两组患者中分别有28.6%和25.5%有过敏性鼻炎,分别)。在一年的随访期内，接种疫苗组的上呼吸道感染频率显着低于未接种疫苗组（37.9%对73%；相对风险[RR]：2.299；95%置信区间[CI]：1.834-2.882；P<0.001）；然而，哮喘发作频率无显著差异(41.9%对45.2%;RR:0.925;95%CI:0.750-1.141;P>0.050).
■在接下来的一年中，流感疫苗显着降低了上呼吸道感染的频率。然而,它不能显著降低阿曼成人哮喘患者哮喘加重的频率.建议进一步研究以支持疫苗在这方面的保护作用。
■这项回顾性队列研究于2018年1月至12月在马斯喀特省进行，阿曼。马斯喀特省9个随机选择的初级保健中心共有466名患者被纳入研究，并在接种疫苗后随访一年。
■大多数患者为女性（70.6%），患有中度持续性哮喘（42.9%）。接种疫苗组中有203名患者（43.6％），未接种疫苗组中有263名患者（56.4％）。两组患者中分别有28.6%和25.5%有过敏性鼻炎,分别)。在一年的随访期内，接种疫苗组的上呼吸道感染频率显着低于未接种疫苗组（37.9%对73%；相对风险[RR]：2.299；95%置信区间[CI]：1.834-2.882；P<0.001）；然而，哮喘发作频率无显著差异(41.9%对45.2%;RR:0.925;95%CI:0.750-1.141;P>0.050).
■在接下来的一年中，流感疫苗显着降低了上呼吸道感染的频率。然而,它不能显著降低阿曼成人哮喘患者哮喘加重的频率.建议进一步研究以支持疫苗在这方面的保护作用。
